9 July 2026: TGA Flags Performance Concerns for TouchBio Chlamydia and Gonorrhoea Self-Test and Suspends ARTG Supply

Summary

On 9 July 2026, the Australian Therapeutic Goods Administration (TGA) published a safety alert stating that it had identified performance concerns with the TouchBio Chlamydia & Gonorrhoea Test for self-testing (for female use) and had suspended its supply under the Australian Register of Therapeutic Goods (ARTG). The alert is directly relevant to IVD self-test registration, performance verification, labelling warnings and post-market surveillance.

Source and Applicability

• Source organisation: TGA Medical Devices
• Original date: 9 July 2026 (2026-07-09)
• Site publication time: 9 July 2026, 17:51
• Source: TGA Medical Devices

This article is compiled from the public TGA safety alert available at: https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/performance-concerns-identified-touchbio-chlamydia-and-gonorrhoea-self-test. Specific requirements remain subject to the latest official publication by the regulatory authority.

Full Translation of Core Content

TGA safety alert: Performance concerns identified with TouchBio Chlamydia and Gonorrhoea self-test

The Australian Therapeutic Goods Administration (TGA) issued a safety alert on 9 July 2026, stating that it had completed a review of the TouchBio Chlamydia & Gonorrhoea Test for self-testing (a chlamydia and gonorrhoea self-test for female use) to verify the performance of this in vitro diagnostic self-test.

TGA stated that the review was undertaken to confirm whether the device could achieve the detection performance claimed by the manufacturer. During the review, TGA also received signals indicating that some users may obtain false negative results after using the product, with infection subsequently identified through other testing methods.

Chlamydia and gonorrhoea are nationally notifiable sexually transmitted infections in Australia. Accurate testing for these infections is important for timely diagnosis, timely treatment and preventing further transmission. Therefore, if a self-test IVD product has a limit of detection or analytical performance that cannot be reproduced, this directly affects public health risk control.

In the review findings, TGA initiated independent laboratory testing to assess the analytical performance of the product, including whether it could reliably detect Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) at the concentration levels claimed by the manufacturer. TGA found that it could not reproduce the manufacturer's analytical performance claims regarding the limit of detection.

Until the manufacturer resolves the issue, TGA considers that the device is not reliable for detecting CT and NG at the claimed concentrations. This means that the product may lead users to obtain false negative results. False negative results may cause missed infections, delayed diagnosis and treatment, and increased risk of continued transmission.

Regarding regulatory outcomes and measures, TGA stated that, after completing the review, the TouchBio Chlamydia & Gonorrhoea Test for self-testing (for female use) was suspended from the Australian Register of Therapeutic Goods (ARTG). During the suspension period, the device must not be lawfully supplied in Australia by the sponsor.

TGA also noted that the sponsor is undertaking further work to address the issues identified in the review, including demonstrating that the device can reliably detect CT and NG at its claimed concentration levels.

For healthcare professionals and consumers, TGA reminds that because the product is intended for self-testing, users should understand its limitations. Based on the above findings, a negative result from the device cannot rule out infection. The device should not replace evaluation by a doctor and is more appropriate as a preliminary screening tool.

If an individual has ongoing risk of infection, a recent history of exposure or persistent symptoms, they should seek further assessment through a healthcare professional or sexual health clinic, including confirmatory testing. Healthcare professionals and services should also be aware of the potential false negative risk associated with the product and consider appropriate follow-up and confirmatory testing for relevant populations in accordance with local clinical practice.

TGA encourages consumers and healthcare professionals to report problems with medical devices; relevant reports will be used in TGA's post-market monitoring of products. TGA also states that it cannot provide advice on individual medical conditions; if an individual is concerned about an adverse event related to a medical device, they should consult a healthcare professional.

AIMEILI Regulatory Interpretation and Business Impact

What this information means for medical device companies

A safety alert of this type issued by TGA should first be treated by companies as regulatory intelligence and a post-market surveillance signal, rather than as ordinary industry news. It directly concerns performance claims for IVD self-test products, independent laboratory verification, false negative risk and suspension of ARTG supply eligibility. This shows that regulatory authorities will continue to verify key performance claims in company submissions during the post-market phase.

For Chinese IVD companies, the key point is not simply to know that a particular product has been suspended, but to review their own products for similar risks: whether there is sufficient evidence to support limit of detection, sensitivity, specificity, sample type, user operating conditions, instructions for use warnings and interpretation of negative results. For self-test products, particular attention should be paid to whether lay users can correctly collect samples, correctly perform the test and correctly understand the test results.

If a company is pursuing registration in Australia, the European Union, ASEAN or other GHWP member states, such cases should be incorporated into performance evaluation and post-market surveillance systems. Where necessary, companies should update risk management files, performance verification plans, labels and instructions for use, complaint handling procedures, CAPA records and distributor communication mechanisms, so as to avoid similar issues being amplified during registration review or post-market inspections.

Which documents should companies prioritise?

It is recommended to prioritise review of the intended use, classification basis, ISO 13485 quality system evidence, risk management file, performance verification data, clinical evaluation or clinical evidence, labels and instructions for use, authorisation documents and existing registration certificates.

Common risks

• Unclear classification determination.
• Incomplete evidence chain in documentation.
• Labels and instructions for use not localised.
• Unclear responsibilities of the authorised representative.
• Insufficient post-market maintenance arrangements.

AIMEILI view

This TGA safety alert is particularly important for Chinese IVD companies because it is not ordinary market news, but a clear regulatory action by a regulator concerning performance claims, independent verification and post-market risk control for self-test in vitro diagnostic products. TGA did not stop at the complaint level; it independently verified the manufacturer's limit of detection performance claims through laboratory testing, ultimately concluded that the relevant performance could not be reproduced, and suspended the product's ARTG supply eligibility. For IVD companies preparing to enter Australia, ASEAN, the EU or other GHWP member markets, this shows that performance evaluation documentation must not only meet registration submission formats, but must also withstand post-market sampling and independent verification by regulators.

From a registration pathway perspective, self-test IVD products generally involve higher user risk because testing takes place in a non-professional environment, and users have limited ability to understand false negatives, false positives and sample collection limitations. When submitting applications, companies should pay particular attention to intended use, target population, sample type, limit of detection, cross-reactivity, interfering substances, clinical performance, user comprehension studies and labels and instructions for use. If a product is intended for home self-testing, regulators often place greater emphasis on whether lay users can correctly collect samples, correctly perform the test, correctly read results and understand the boundaries of negative results.

From a technical file perspective, companies should re-examine whether performance evaluation reports can support all performance claims in the labelling. In particular, limit of detection, sensitivity, specificity, positive/negative agreement, coverage of different strains or targets, sample stability, transport conditions and end-user operational deviations should form a clear evidence chain. If a manufacturer reuses the same set of performance data across multiple markets, it is also necessary to determine whether TGA in Australia, the EU IVDR, ASEAN countries and Middle East markets impose additional local requirements for self-test products.

From a post-market maintenance perspective, this information reminds companies that they must establish complaint handling, trend analysis, CAPA, batch traceability and regulatory reporting mechanisms that can actually operate. False negative risk is not a simple customer complaint; it may affect public health management, clinical diagnosis and treatment pathways, and infection transmission control. Once a company identifies a similar risk, it should promptly assess whether it is necessary to update the risk management file, instructions for use warnings, user training materials and distributor communication documents, and, where necessary, initiate field safety corrective action or proactive recall.

AIMEILI recommends that Chinese IVD companies include such TGA safety alerts in their regulatory intelligence tracking lists. For self-test, POCT, infectious disease testing, women's health testing and home-use diagnostic products that are already marketed or planned for registration, three matters should be prioritised: first, whether performance claims are supported by sufficient and reproducible verification data; second, whether labels and instructions for use clearly state that a negative result cannot completely rule out infection; third, whether the post-market surveillance system can promptly identify false negative trends and create records of regulatory communication. Such preparation will directly affect companies' long-term compliance capability in GHWP member state markets.

FAQ

Can the TGA safety alert of 9 July 2026 regarding TouchBio Chlamydia and Gonorrhoea self-test performance concerns be used directly as a basis for regulatory submission?

No. This article is intended for preliminary understanding and project assessment. A formal submission must still be based on the latest requirements of the target country's regulatory authority, the product classification conclusion and the company's actual documentation.

What should companies do first after seeing such an update?

Companies should first conduct a documentation gap assessment to confirm whether the update affects the registration pathway, technical file, labelling, quality system or post-market maintenance.

Content Review and Scope

Content author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Team

Source principle: Priority is given to official regulatory authorities, international organisations, standards organisations and public regulatory materials; industry media and project experience are used only as auxiliary judgment references.

Scope: This article is intended for preliminary understanding, document preparation and project planning. It does not replace the formal requirements, testing conclusions or legal opinions of the target country's regulatory authority.

Need to Assess Your Registration Pathway?

Please provide the product name, intended use, target countries and existing documentation basis. AIMEILI can assist in assessing the registration pathway, documentation gaps and compliance risks.

Contact AIMEILI